Sino Biopharmaceutical (HK:1177) has released an update.Don't Miss out on Research Tools:Discover the latest stocks recommended by top Wall ...

The deal allows Merck to take over development of privately held LaNova Medicines' LM-299, the companies said on Thursday.

Merck MRK announced that it has entered into an exclusive licensing deal with China-based privately-held biotech company ...

MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

SINO BIOPHARM (01177.HK) injected its capital to the equity interests of LaNova Medicines with its self-raised funds, and ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...